Lv3
238 积分 2021-01-12 加入
Maintenance after first-line treatment for advanced soft tissue sarcoma
7天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1个月前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
1个月前
已完结
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
1个月前
已完结
Immunotherapies for hepatocellular carcinoma
1个月前
已完结
Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma
1个月前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
1个月前
已完结
Hallmarks of liver cancer: Therapeutic implications
1个月前
已完结
The Latest Progress in the Application of Telitacicept in Autoimmune Diseases
4个月前
已完结
AI-driven glomerular morphology quantification: a novel pipeline for assessing basement membrane thickness and podocyte foot process effacement in kidney diseases
5个月前
已完结
皖公网安备34019202002308
